Production and Therapeutic Use of a Factor XI Concentrate from Plasma

Summary

Factor XI deficiency is an uncommon bleeding disorder usually manifested by excessive bleeding after surgery or trauma. Until recently the only effective therapy has been fresh-frozen plasma (FFP) infusion. We describe the efficacy and safety of a new factor XI concentrate produced from human donor plasma by a modification of the method used for antithrombin III concentrate. The mean recovery of factor XI in the circulation measured on 62 occasions was approximately 91% of the injected dose, and the mean half-disappearance-time was 52 h. The concentrate was used for 31 invasive procedures in 30 patients, including 16 patients who had a definite bleeding tendency on previous occasions, with normal haemostasis being achieved in all but 1. Only 1 patient (previously experiencing allergy to FFP) experienced adverse effects during infusion. Monitoring of liver function tests and viral antibody status in suitable patients has shown no evidence of transmission of hepatitis viruses, HIV-1 or parvovirus B19.

We conclude that this concentrate provides effective treatment for patients with factor XI deficiency. Preliminary results suggest safety from virus transmission, but this needs to be established in further studies of previously untreated patients.

• References

• 1 Bolton-Maggs PHB, Young Wan-Yin B, McGraw AH, Slack J, Kernoff PBA. Inheritance and bleeding in factor XI deficiency. Br J Haematol 1988; 69: 521-528
• 2 Smith JK, Winkelman L, Evans DR, Haddon ME, Sims G. A pasteurized antithrombin III concentrate for clinical use. Vox Sang 1985; 48: 325-332
• 3 Gomall AG, Bardawill CJ, David MM. Determination of serum protein by means of the biuret reaction. J Biol Chem 1949; 177: 751-766
• 4 Zall DM, Fisher D, Carner MQ. Photometric determination of chlorides in water. Anal Chem 1956; 28: 1665-1668
• 5 Saffran M, Denstedt OF. A rapid method for the determination of citric acid. J Biol Chem 1948; 175: 849-855
• 6 Peterson GL. A simplified method for the analysis of inorganic phosphate in the presence of interfering substances. Anal Biochem 1978; 84: 164-172
• 7 Snape TJ, Griffiths D, Vallet L, Wesley ED. The assay of pre-kallikrein activator in human blood products. Dev Biol Standard 1979; 44: 115-120
• 8 Fischer KA. A new method for the analytical determination of the water content of liquids and solids. Angew Chem 1935; 48: 394-396
• 9 Mannucci PM, Colombo M. Revision of the protocol recommended for studies of safety from hepatitis of clotting factor concentrates. Thromb Haemostas 1989; 61: 532-534
• 10 Kingdon HS, Lundblad RL, Veltkamp JJ, Aronson DL. Potentially thrombogenic materials in factor IX concentrates. Thromb Diath Haemorrh 1975; 33: 617-631
• 11 Nossel HL, Niemetz J, Mibashan RS, Schulze WG. The measurement of factor XI (plasma thromboplastin antecedent): diagnosis and therapy of the congenital deficiency state. Br J Haematol 1966; 12: 133-144
• 12 Rosenthal RL, Sloan E. PTA (factor XI) levels and coagulation studies after plasma infusions in PTA-deficient patients. J Lab Clin Med 1965; 66: 709-714
• 13 Bick RL, Adams T, Radack K. Surgical hemostasis with a factor XI-containing concentrate. J Am Med Ass 1974; 229: 163-165
• 14 Rapaport SI, Yettra M. PTA (factor XI) levels after transfusion in patients with PTA deficiency. Bibliotheca Haematologica 1965; 23: 1352-1353
• 15 Horowitz HI, Fujimoto MM. Survival of factor XI in vitro and in vivo. Transfusion 1965; 5: 539-542
• 16 Rizza CR, Jones P. Management of patients with inherited blood coagulation defects. In: Haemostasis and Thrombosis. Bloom AL, Thomas DP. (eds). Churchill Livingstone; Edinburgh: (2nd Edition). 1987. pp 465-493
• 17 Rapaport SI, Proctor RR, Patch MJ, Yettra M. The mode of inheritance of PTA deficiency: evidence for the existence of major PTA deficiency and minor PTA deficiency. Blood 1961; 18: 149-165
• 18 Mammen EF. Factor XI deficiency. Semin Thromb Haemostas 1983; 9: 34-35
• 19 Sidi A, Seligsohn U, Jonas P, Many M. Factor XI deficiency: detection and management during urological surgery. J Urol 1978; 119: 528-530
• 20 Leiba H, Ramot B, Many A. Heredity and coagulation studies in ten families with factor XI (plasma thromboplastin antecedent) deficiency. Br J Haematol 1965; 11: 654-665
• 21 Ragni MV, Sinha D, Seaman F, Lewis JH, Spero JA, Walsh PN. Comparison of bleeding tendency, factor XI coagulant activity and factor XI antigen in 25 factor XI-deficient kindreds. Blood 1985; 65: 719-724
• 22 Asakai R, Chung DW, Davie EW, Seligsohn U. Factor XI deficiency in Ashkenazi Jews in Israel. N Engl J Med 1991; 325: 153-158
• 23 Hancock JF, Weiland K, Pugh RE, Martinowitz U, Schulman S, Kakkar W, Kernoff PBA, Cooper DN. A molecular genetic study of factor XI deficiency. Blood 1991; 77: 1942-1948
• 24 Study Group of UK Haemophilia Centre Directors on Transmission of Blood Borne Viruses by Concentrates. Effect of dry-heating of coagulation factor concentrates at 80° for 72 hours on transmission of non-A, non-B hepatitis. Lancet 1988; ii: 814-816
• 25 Colvin BT. Prevention of hepatitis C infection in haemophiliacs. Lancet 1990; i: 1474